MURFREESBORO, TN / ACCESS Newswire / April 15, 2025 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the first quarter ended March 31, 2025. NHI plans ...

VANCOUVER, BC / ACCESS Newswire / April 15, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that Company completed its previously ...

GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.

New survey insights from Brazilian healthcare leaders highlight financial, regulatory, and interoperability barriers limiting EHR expansion despite significant investments. MIAMI, FLORIDA / ACCESS ...

Study Confirms Nasdepi® Dose Enabling Pivotal Biocomparability Study and Commercial Manufacturing RALEIGH, NORTH CAROLINA / ACCESS Newswire / April 15, 2025 / Belhaven Biopharma, a leader in ...

ATLANTA, GA / ACCESS Newswire / April 15, 2025 / May is Arthritis Awareness Month, and the Arthritis Foundation, the number one resource for arthritis resources and information, is introducing Green ...

Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the ...

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the ...

UK-based blood testing company Thriva has joined forces with medical device manufacturer Tasso to use their innovative blood testing technology to tackle needle phobia, a condition that affects at ...

CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and ...

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the ...

Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that ...